OTLK supply chain intelligence for Outlook Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Outlook Therapeutics, Inc. (OTLK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ATLAS-SCIENCES-LLC | ATLAS-SCIENCES-LLC | 92% | On March 16, 2026, the Company entered into a note purchase agreement with Atlas Sciences, LLC ("Atlas"), pursuant to which the Company issued an unsecured promissory note (the "March 2026 Note") wit… |
| H-C-WAINWRIGHT-CO-LLC | H-C-WAINWRIGHT-CO-LLC | 90% | The Company will pay H.C. Wainwright a commission equal to 3% of the aggregate gross proceeds of any sale of Shares under the Sales Agreement. |
| SELEXIS-SA | SELEXIS-SA | 85% | We have in-licensed certain technology from Selexis SA, or Selexis, that we used to research and develop our product candidates. |
| BTIG-LLC | BTIG-LLC | 80% | The Company terminated, effective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”) with BTIG, LLC with respect to an at-the-market o… |
| KLRS | Kalaris Therapeutics, Inc. | 72% | Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We inten… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from REGN graph: on, patient education, reimbursement and market access, trade and distributi… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CENCORA | CENCORA | 90% | If we are unable to establish sales and marketing capabilities for any approved product, whether on our own or through collaborations, including through the strategic collaboration agreement with Cen… |
| SYNTONE-VENTURES-LLC | SYNTONE-VENTURES-LLC | 80% | In May 2020, we entered into a stock purchase agreement with Syntone Ventures LLC, or Syntone, pursuant to which we sold and issued, in a private placement in June 2020, 800,000 shares of our common … |
| KLRS | Kalaris Therapeutics, Inc. | 72% | Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS g… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| ATLAS-SCIENCES-LLC | ATLAS-SCIENCES-LLC | 62% | Trigger Event has not resulted in an Event of Default. During the first three months ended March 31, 2026, the Company completed multiple conversions of outstanding principal and accrued interest und… |
| AVONDALE-CAPITAL-LLC | AVONDALE-CAPITAL-LLC | 62% | or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors The fo… |
| BEIJING-SYNTONE-BIOPHARMA-LTD | BEIJING-SYNTONE-BIOPHARMA-LTD | 62% | L in August 2023. Loss on Equity Method Investment Loss on equity method investment represents our share of the loss from Beijing Syntone Biopharma Ltd, or Syntone JV. Interest Income Interest income… |
| BTIG-LLC | BTIG-LLC | 62% | ty of the cash payments related to the workforce reduction will be substantially complete by the end of the third calendar quarter of 2025, we may incur other charges or cash expenditures not current… |
| COORDINATION-GROUP | COORDINATION-GROUP | 62% | e abbreviated approval pathway that are still being worked out by the FDA. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date… |
| ESSEX-BIO-TECHNOLOGY-LTD | ESSEX-BIO-TECHNOLOGY-LTD | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| SHANGHAI-HENLIUS-BIOTECH-INC | SHANGHAI-HENLIUS-BIOTECH-INC | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| STADA-ARZNEIMITTEL-AG | STADA-ARZNEIMITTEL-AG | 62% | ecuted a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA’s safety profile over the curre… |
| STREETERVILLE-CAPITAL-LLC | STREETERVILLE-CAPITAL-LLC | 62% | hange in Fair Value of Warrant Liability We recognized income related to the decrease in the fair value of our common stock warrant liability in both fiscal years 2024 and 2023. This income was attri… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| OTLK-DEBT | Debt stack $545.0M | 90% | Market cache reports total debt of $545.0M. |
| OTLK-DEBT-11620 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-09-30. |
| OTLK-DEBT-11619 | Warrants outstanding: 56828913 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| OTLK-OWNER-SCHONFELD-STRATEGIC-ADVISORS-LLC | Schonfeld Strategic Advisors Llc | 95% | 13F/ownership overlay lists Schonfeld Strategic Advisors Llc; shares held 2,441,355; ownership 2.33%; value $564,441; as of 2025-12-31. |
| OTLK-OWNER-SUSQUEHANNA-INTERNATIONAL-GROUP-LLP | Susquehanna International Group, LLP | 95% | 13F/ownership overlay lists Susquehanna International Group, LLP; shares held 172,022; ownership 0.16%; value $39,771; as of 2025-12-31. |
| OTLK-OWNER-WARBERG-ASSET-MANAGEMENT-LLC | Warberg Asset Management LLC | 95% | 13F/ownership overlay lists Warberg Asset Management LLC; shares held 275,000; ownership 0.26%; value $63,579; as of 2026-03-31. |
| OTLK-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 404,542; ownership 0.39%; value $93,530; as of 2025-12-31. |
| OTLK-OWNER-COMMONWEALTH-EQUITY-SERVICES-LLC | Commonwealth Equity Services, LLC | 95% | 13F/ownership overlay lists Commonwealth Equity Services, LLC; shares held 470,000; ownership 0.45%; value $108,663; as of 2026-03-31. |
| OTLK-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 316,464; ownership 0.30%; value $73,166; as of 2025-12-31. |
| OTLK-OWNER-GILPIN-WEALTH-MANAGEMENT-LLC | Gilpin Wealth Management, LLC | 95% | 13F/ownership overlay lists Gilpin Wealth Management, LLC; shares held 600,162; ownership 0.57%; value $138,757; as of 2026-03-31. |
| OTLK-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | Vanguard Capital Management LLC | 95% | 13F/ownership overlay lists Vanguard Capital Management LLC; shares held 1,967,160; ownership 1.88%; value $454,807; as of 2026-03-31. |
| OTLK-OWNER-MARSHALL-WACE-LLP | Marshall Wace LLP | 95% | 13F/ownership overlay lists Marshall Wace LLP; shares held 298,456; ownership 0.29%; value $69,003; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| OCUL | Ocular Therapeutix, Inc. | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| KLRS | Kalaris Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| ARTV | Artiva Biotherapeutics, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 50.00 | 2 | |
| ABBV | AbbVie Inc. | 50.00 | 2 | |
| ACET | Adicet Bio, Inc. | 50.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 50.00 | 2 | |
| ALLR | Allarity Therapeutics, Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| GKOS | Glaukos Corporation | 50.00 | 2 | |
| INAB | IN8bio, Inc. | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 | |
| IRIX | IRIDEX Corporation | 50.00 | 2 | |
| GNLX | Genelux Corporation | 50.00 | 2 |